Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Rheuminations: Rheumatologists Seek Better Understanding of Fibrosing Disorders

  |  Issue: December 2013  |  

Dr. Helfgott is physician editor of The Rheumatologist and associate professor of medicine in the division of rheumatology, immunology, and allergy at Harvard Medical School in Boston.

References

  1. Cole TB. The cover. JAMA. 2013;309:1562.
  2. Varga, J. Illness and art: The legacy of Paul Klee. Current Opin Rheumatol. 2004;16:714-717.
  3. Rodnan GP, Benedek TG. An historical account of the study of progressive systemic sclerosis (diffuse scleroderma). Ann Intern Med. 1962:57;307-319.
  4. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis. Arthritis Rheum. 2013:65;2737-2747.
  5. Akhmetshina A, Palumbo K, Dees C, Bergmann C. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun. 2012;3:735.
  6. Kilbourne EM, Riagu-Perez JG, Heath CW, Zack MM. Clinical epidemiology of toxic-oil syndrome. N Engl J Med. 1983;309:1408-1414.
  7. Epidemiologic notes and reports eosinophilia-myalgia syndrome—New Mexico. MMWR. 1989:38; 765-767.
  8. Wermuth PJ, Jimenez SA. Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: Establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis. J Immunol. 2012; 189:318-327.

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles

    Targeted Therapy for Scleroderma Fibrosis

    Scleroderma, or systemic sclerosis (SSc), is an autoimmune disease characterized by vasculopathy and fibrosis. Although relatively rare, with a prevalence in North America of approximately 300 per 1 million people, SSc is associated with significant morbidity and high rates of mortality.1 Patients with scleroderma have four times greater mortality than age- and sex-matched controls, with…

    More Effective Antifibrotic Therapies for Systemic Sclerosis in Development; Adverse Events A Concern

    Systemic sclerosis (SSc) is a rare disease affecting about 49,000 U.S. adults, and it is strongly associated with high levels of morbidity and mortality.1 Of the few available antifibrotic therapies, none is targeted for SSc. However, reason for optimism exists for antifibrotic treatments in early development and clinical trials, says Jörg H.W. Distler, MD, Heisenberg Professor…

    Labored Breathing

    Strategies to diagnose and manage dyspnea in the scleroderma patient